June 04, 2019 Asco 2019 – KRAS chase heats up with Amgen data Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
April 26, 2019 Astra’s first attempt fails, but there’s no giving up on KRAS After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
